Business Context and Reporting Period
This Form 8-K is filed by Fluidigm Corporation (noted as Standard BioTools Inc. in metadata) on January 9, 2017. The report serves to disclose preliminary financial results for the fourth quarter and full year 2016, alongside an update to investor presentation materials.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing the preliminary fourth quarter and full year 2016 revenue figures, but the actual data points are not included in the provided text.
Material Changes
The filing announces the issuance of preliminary revenue results for Q4 and full-year 2016. No specific comparative data or percentage changes versus prior periods are detailed in the text of this report.
Guidance, Outlook, and Risks
Under Item 7.01, the company updated its investor presentation information (Exhibit 99.2). The filing does not contain explicit management commentary, forward-looking guidance, risk factors, or details on contingencies within the main text; these are presumed to be contained in the referenced exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific preliminary revenue figures for Q4 and full-year 2016.
- Examine Exhibit 99.2 (Investor Presentation) for updated guidance, strategic outlook, and management commentary.
- Verify the discrepancy between the metadata company name ("Standard BioTools Inc.") and the registrant name in the filing ("Fluidigm Corporation").
- Note that the financial data in this 8-K is preliminary and not deemed "filed" for Section 18 liability purposes under the Exchange Act.